S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33

Zymeworks Stock Forecast, Price & News

-1.24 (-4.17 %)
(As of 09/24/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume589,599 shs
Average Volume476,547 shs
Market Capitalization$1.32 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter.

Zymeworks logo

About Zymeworks

Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.13 out of 5 stars

Medical Sector

420th out of 1,351 stocks

Pharmaceutical Preparations Industry

207th out of 664 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Zymeworks (NYSE:ZYME) Frequently Asked Questions

Is Zymeworks a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last twelve months. There are currently 3 hold ratings, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Zymeworks stock.
View analyst ratings for Zymeworks
or view top-rated stocks.

What stocks does MarketBeat like better than Zymeworks?

Wall Street analysts have given Zymeworks a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zymeworks wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Zymeworks

How were Zymeworks' earnings last quarter?

Zymeworks Inc. (NYSE:ZYME) released its quarterly earnings results on Wednesday, August, 4th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by $0.26. The company had revenue of $1.77 million for the quarter, compared to the consensus estimate of $7.26 million. Zymeworks had a negative trailing twelve-month return on equity of 57.78% and a negative net margin of 1,073.23%.
View Zymeworks' earnings history

How has Zymeworks' stock been impacted by Coronavirus?

Zymeworks' stock was trading at $32.26 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ZYME stock has decreased by 11.6% and is now trading at $28.52.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ZYME?

8 equities research analysts have issued 12-month target prices for Zymeworks' shares. Their forecasts range from $38.00 to $74.00. On average, they anticipate Zymeworks' stock price to reach $51.57 in the next twelve months. This suggests a possible upside of 80.8% from the stock's current price.
View analysts' price targets for Zymeworks
or view top-rated stocks among Wall Street analysts.

Who are Zymeworks' key executives?

Zymeworks' management team includes the following people:
  • Ali Tehrani, President, Chief Executive Officer & Director
  • Neil Klompas, Chief Financial Officer & EVP-Business Operations
  • Anthony J. Polverino, Chief Scientific Officer & EVP-Early Development
  • Neil Josephson, Chief Medical Officer
  • Mark Hollywood, Senior VP-Technical & Manufacturing Operations

What is Ali Tehrani's approval rating as Zymeworks' CEO?

9 employees have rated Zymeworks CEO Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among Zymeworks' employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend.

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA).

When did Zymeworks IPO?

(ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager.

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by many different institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (9.28%), Perceptive Advisors LLC (9.28%), FMR LLC (7.47%), Credit Suisse AG (5.06%), Morgan Stanley (4.99%) and Morgan Stanley (4.99%). Company insiders that own Zymeworks stock include Ali Tehrani, Diana Hausman, James Priour, Kathryn O'driscoll, Neil A Klompas and Troy Cox.
View institutional ownership trends for Zymeworks

Which institutional investors are selling Zymeworks stock?

ZYME stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Wells Fargo & Company MN, UBS Asset Management Americas Inc., Price T Rowe Associates Inc. MD, Point72 Asset Management L.P., American Century Companies Inc., Handelsbanken Fonder AB, and Alyeska Investment Group L.P.. Company insiders that have sold Zymeworks company stock in the last year include Ali Tehrani, Diana Hausman, James Priour, Kathryn O'driscoll, and Neil A Klompas.
View insider buying and selling activity for Zymeworks
or view top insider-selling stocks.

Which institutional investors are buying Zymeworks stock?

ZYME stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Morgan Stanley, Armistice Capital LLC, Northern Trust Corp, Franklin Resources Inc., Russell Investments Group Ltd., and Nuveen Asset Management LLC. Company insiders that have bought Zymeworks stock in the last two years include Ali Tehrani, and Troy Cox.
View insider buying and selling activity for Zymeworks
or or view top insider-buying stocks.

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $28.52.

How much money does Zymeworks make?

Zymeworks has a market capitalization of $1.32 billion and generates $38.95 million in revenue each year. The company earns $-180,550,000.00 in net income (profit) each year or ($3.58) on an earnings per share basis.

How many employees does Zymeworks have?

Zymeworks employs 354 workers across the globe.

What is Zymeworks' official website?

The official website for Zymeworks is www.zymeworks.com.

Where are Zymeworks' headquarters?

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The company can be reached via phone at (604) 678-1388 or via email at [email protected].

This page was last updated on 9/25/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.